44
Views
0
CrossRef citations to date
0
Altmetric
CASE REPORT

Lessons from Multiple Infections Such as Lymphoma Complicated with Pneumocystis Infection: A Case Report

, , , , &
Pages 1583-1588 | Received 26 Jan 2024, Accepted 19 Apr 2024, Published online: 22 Apr 2024
 

Abstract

Background

Lymphoma is complicated by intricate infections, notably Pneumocystis jirovecii pneumonia (PJP), marked by rapid progression, respiratory failure, and high mortality. Rapid diagnosis of PJP and effective administration of the first-line treatment trimethoprim-sulfamethoxazole (TMP-SMX) are important. For patients intolerant to TMP-SMX, selecting appropriate alternatives is challenging, necessitating careful decisions to optimize diagnosis and treatment. We present a lymphoma case complicated by PJP, illustrating medication adjustment until a positive response was observed.

Case Description

A 41-year-old male patient with lymphoma presented with a week-long history of fever, fatigue, cough, sputum, chest tightness, and exertional dyspnea, unresponsive to treatment. Routine laboratory examinations revealed no pathogenic bacteria. PJ and Mycobacterium tuberculosis (MTB) were detected in bronchoalveolar lavage fluid (BALF) using metagenomic next-generation sequencing (mNGS). On Day 1 of admission, meropenem, TMP-SMX, and rifampicin+isoniazid+levofloxacin were administered. However, the patient developed drug-induced hepatotoxicity and gastrointestinal adverse reactions after six days of treatment. After a multidisciplinary team discussion, anti-tuberculosis therapy was stopped because of insufficient evidence of tuberculosis infection. A reduced dose of TMP-SMX with micafungin was used for PJP; however, symptoms persisted and repeated computed tomography showed extensive deterioration of bilateral pulmonary plaques. The PJP regimen was modified to include a combination of TMP-SMX and caspofungin. Due to the high fever and elevated infection indices, the patient was treated with teicoplanin to enhance the anti-infection effects. By Day 13, the patient’s temperature had normalized, and infection control was achieved by Day 30. CT revealed that the infection in both lung lobes fully resolved. Subsequently, lymphoma treatment commenced.

Conclusion

BALF-NGS facilitates early and rapid diagnosis of PJP. mNGS reads of MTB bacillus <5 may indicate a bacterial carrier state, warranting other detection techniques to support it. There is insufficient evidence for using TMP-SMX with micafungin to treat PJP; however, TMP-SMX combined with caspofungin is suitable.

Data Sharing Statement

Data will be provided by the corresponding author upon reasonable request.

Ethics Approval and Consent to Participate

This study was supported by the Ethics Committee of Hangzhou Red Cross Hospital (No.: 2023YS018) and was carried out in accordance with the ethical standards of the Declaration of Helsinki.

Consent Statement

Written informed consent was obtained from the patient and his immediate family members for the publication of any potentially identifiable images or data included in this case report prior to inclusion.

Acknowledgments

The authors thank all the clinical staff who contributed to the study.

Author Contributions

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Disclosure

All authors declare that the research is conducted in the absence of any commercial relations or financial relationships of interest that might be a constant source of interest.

Additional information

Funding

This research was supported by the Hangzhou Biomedicine and Health Industry Development Project (No. 2022WJC210), and the Zhejiang Province Traditional Chinese Medicine Science and Technology Plan Project (No. 2021ZB214).